Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
224 hedge funds and large institutions have $7.19B invested in Sage Therapeutics in 2017 Q4 according to their latest regulatory filings, with 79 funds opening new positions, 72 increasing their positions, 63 reducing their positions, and 28 closing their positions.
233% more funds holding in top 10
Funds holding in top 10: 3 → 10 (+7)
193% more capital invested
Capital invested by funds: $2.46B → $7.19B (+$4.73B)
182% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 28
29% more funds holding
Funds holding: 174 → 224 (+50)
15% more call options, than puts
Call options by funds: $303M | Put options by funds: $264M
14% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 63
2.17% more ownership
Funds ownership: 105.18% → 107.36% (+2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$159M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$60.2M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$56.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.6M |
| 5 |
BlackRock
New York
|
+$47.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$106M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$72M |
| 3 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$37.8M |
| 4 |
O
OppenheimerFunds
New York
|
-$30.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$22M |
SAGE Hedge Fund Activity: Q4 2017 in Review
224 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2017, worth a combined $7.19B — up 193% from $2.46B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new SAGE positions and 28 closed out — a net gain of 51 holders — while 72 added to existing stakes and 63 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $159M. The largest seller was Bank of New York Mellon, cutting an estimated $106M.
- 224 institutional investors held Sage Therapeutics (SAGE) as of Q4 2017, up from 174 in Q3 2017.
- Funds reported $7.19B of Sage Therapeutics stock for Q4 2017, up 193% quarter-over-quarter.
- 79 funds opened new Sage Therapeutics positions in Q4 2017 and 28 closed out, a net change of +51 holders.
- The largest Sage Therapeutics buyer in Q4 2017 was T. Rowe Price Associates, an estimated $159M added.
- The largest Sage Therapeutics seller in Q4 2017 was Bank of New York Mellon, an estimated $106M sold.
Based on aggregated 13F filings for Q4 2017.